Data Breach. When transferring Confidential Information, all communications between GSK and ITEOS will use encryption methods agreed to by the Parties. Upon discovering any suspected or actual unauthorized disclosure, loss or theft of Confidential Information (a “Data Security Breach”) ​. The Parties shall work with each other in good faith to identify a root cause and remediate the Data Security Breach.

Data Breach. When transferring Confidential Information, all communications between GSK and IDEAYA will use encryption methods agreed to by the Parties. Upon discovering any suspected or actual unauthorized disclosure, loss or theft of Confidential Information (a “Data Security Breach”) IDEAYA will send an e-mail to ​ notifying GSK, and upon discovering any suspected or actual Data Security Breach, GSK will send an e-mail to ​, notifying IDEAYA. The Parties shall work with each other in good faith to identify a root cause and remediate the Data Security Breach.

Data. All Data generated in connection with any Development or Commercial activities with respect to any Product conducted solely by or on behalf of Ovid and its Affiliates and licensees (other than Licensee) (the “Ovid Data”) shall be the sole and exclusive property of Ovid or such Affiliates or licensees, as applicable. All Data generated in connection with any Development or Commercial activities with respect to any Product conducted solely by or on behalf of Licensee or its Affiliates or Sublicensees (the “Licensee Data”) shall be the sole Certain identified information marked with ​ has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

Data. Ji Xing shall (and shall cause its Affiliates and sublicensees to) ​.

Data. During the Research Term, Fulcrum # will use, and will cause its Affiliates and permitted subcontractors to use, any data generated in performance of any Research Activities (including any data in any Data Package) (“Research Data”) solely to perform the Fulcrum Research Activities in accordance with this Agreement and # will only transfer, make available, deliver or disclose Research Data to such Affiliates and permitted subcontractors performing such Fulcrum Research Activities. If [[MyoKardia:Organization]] designates a Lead Cardiomyopathy Target, then for ​ after the end of the Research Term (“Exclusivity Period”), Fulcrum # will not use (and will cause its Affiliates and permitted subcontractors to not use) any Research Data for any reason and # will not transfer, make available, deliver or disclose Research Data to any Third Party

Data. [[Aravive:Organization]] shall solely own all Data generated by [[Aravive:Organization]]. For clarity, all Data Controlled by [[Aravive:Organization]] as of the Effective Date and during the Term are included in the [[Aravive:Organization]] Licensed Know-How and licensed to [[3D Medicines:Organization]] under Section 2.1(a). [[3D Medicines:Organization]] shall solely own all Data generated by [[3D Medicines:Organization]] in the Development of Licensed Products in the Field in the [[3D Medicines:Organization]] Territory. [[3D Medicines:Organization]] hereby grants to [[Aravive:Organization]] # an irrevocable, perpetual, royalty-free, fully paid-up, non-exclusive license, with the right to grant sublicenses, to use such Data generated and owned by [[3D Medicines:Organization]] for the Development, Manufacture and Commercialization of the Licensed Compound or Licensed Products in the [[Aravive:Organization]] Territory, and # upon termination of the Agreement (other than termination of the Agreement by [[3D Medicines:Organization]] pursuant to [Sections 13.4 or 13.5]5]), an irrevocable, perpetual, royalty-free, fully paid-up, non-exclusive license, with the right to grant sublicenses, to use such Data generated and owned by [[3D Medicines:Organization]] for the Development, Manufacture and Commercialization of the Licensed Compound or Licensed Products in the Field in the [[3D Medicines:Organization]] Territory. Notwithstanding the foregoing, no rights shall be granted by either Party to the other Party under this [Section 9.1(a)] with respect to the Development, Manufacture or Commercialization of any product containing the Licensed Compound together with one or more Drug Substances other than the Licensed Compound or for use in combination with one or more Drug Substances other than the Licensed Compound.

Data. The information on the Asset Schedule is true and correct in all material respects as of the date of such information. With respect to each Performing Mortgage Loan and Re-Performing Mortgage Loan, as of the Purchase Date, the most recent FICO listed on the Asset Schedule was no more than two hundred and seventy (270) days old. As of the Purchase Date, with respect to each Mortgage Loan no BPO valuation listed on the Asset Schedule was more than two hundred and seventy (270) days old.

Data. Ji Xing shall (and shall cause its Affiliates and sublicensees to) promptly transfer and assign to [[Cytokinetics:Organization]], at no cost to [[Cytokinetics:Organization]], all data generated from the Development of the Product, including all Clinical Trials conducted by or on behalf of Ji Xing, its Affiliates and sublicensees, and all pharmacovigilance data (including all adverse event databases) relating to the Product in the Territory.

Data. All Data generated in connection with any Development or Commercial activities with respect to any Product conducted solely by or on behalf of Ovid and its Affiliates and licensees (other than Licensee) (the “Ovid Data”) shall be the sole and exclusive property of Ovid or such Affiliates or licensees, as applicable. All Data generated in connection with any Development or Commercial activities with respect to any Product conducted solely by or on behalf of Licensee or its Affiliates or Sublicensees (the “Licensee Data”) shall be the sole

Data. [[GlycoMimetics:Organization]] shall solely own all Data generated by or on behalf of [[GlycoMimetics:Organization]]. For clarity, all Data Controlled by [[GlycoMimetics:Organization]] are included in the [[GlycoMimetics:Organization]] Licensed Know-How and licensed to Apollomics under Section 2.1. Apollomics shall solely own all Data generated by or on behalf of Apollomics in the Development, Manufacture, and Commercialization of Licensed Products in the Field in the Apollomics Territory. Apollomics hereby grants to [[GlycoMimetics:Organization]] # a royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses through multiple tiers, to use such Data generated and owned by Apollomics for all purposes in the [[GlycoMimetics:Organization]] Territory, and # upon expiration or termination of the Agreement (other than termination of the Agreement by Apollomics pursuant to Sections 13.4 or 13.5), an irrevocable, perpetual, royalty-free, fully paid-up, non-exclusive license, with the right to grant sublicenses through multiple tiers, to use such Data generated and owned by Apollomics for all purposes in the Apollomics Territory (in addition to the license granted in clause (i) which shall become perpetual and irrevocable upon such expiration or termination). Upon expiration of this Agreement, [[GlycoMimetics:Organization]] hereby grants to Apollomics an irrevocable, perpetual, royalty-free fully paid-up, non-exclusive license, with the right to grant sublicenses through multiple tiers, to use such Data generated and owned by [[GlycoMimetics:Organization]] for all purposes in the Apollomics Territory.